Operator: Good morning and welcome to the Intellia Therapeutics First Quarter 2023 Financial Results Conference Call. My name is Drew and I will be your conference operator today.
Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023Plans to submit IND
CAMBRIDGE, Mass., March 21, 2023 Intellia Therapeutics, Inc. , a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based. | March 21, 2023
Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema - read this article along with other careers information, tips and advice on BioSpace
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on.